236 related articles for article (PubMed ID: 24500884)
1. Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung.
Stjernström A; Karlsson C; Fernandez OJ; Söderkvist P; Karlsson MG; Thunell LK
Cancer Med; 2014 Apr; 3(2):337-48. PubMed ID: 24500884
[TBL] [Abstract][Full Text] [Related]
2. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
3. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
4. INPP4B and PTEN Loss Leads to PI-3,4-P2 Accumulation and Inhibition of PI3K in TNBC.
Reed DE; Shokat KM
Mol Cancer Res; 2017 Jun; 15(6):765-775. PubMed ID: 28196852
[TBL] [Abstract][Full Text] [Related]
5. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
6. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
[TBL] [Abstract][Full Text] [Related]
8. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
9. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
[TBL] [Abstract][Full Text] [Related]
10. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
[TBL] [Abstract][Full Text] [Related]
11. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
Agell L; Hernández S; Salido M; de Muga S; Juanpere N; Arumí-Uria M; Menendez S; Lorenzo M; Lorente JA; Serrano S; Lloreta J
Mod Pathol; 2011 Mar; 24(3):443-52. PubMed ID: 21113138
[TBL] [Abstract][Full Text] [Related]
12. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
Pu X; Hildebrandt MA; Lu C; Lin J; Stewart DJ; Ye Y; Gu J; Spitz MR; Wu X
Lung Cancer; 2011 Jan; 71(1):82-8. PubMed ID: 20447721
[TBL] [Abstract][Full Text] [Related]
13. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
14. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
Fedele CG; Ooms LM; Ho M; Vieusseux J; O'Toole SA; Millar EK; Lopez-Knowles E; Sriratana A; Gurung R; Baglietto L; Giles GG; Bailey CG; Rasko JE; Shields BJ; Price JT; Majerus PW; Sutherland RL; Tiganis T; McLean CA; Mitchell CA
Proc Natl Acad Sci U S A; 2010 Dec; 107(51):22231-6. PubMed ID: 21127264
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
[TBL] [Abstract][Full Text] [Related]
16. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
Singh B; Reddy PG; Goberdhan A; Walsh C; Dao S; Ngai I; Chou TC; O-Charoenrat P; Levine AJ; Rao PH; Stoffel A
Genes Dev; 2002 Apr; 16(8):984-93. PubMed ID: 11959846
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma.
Chiosea SI; Grandis JR; Lui VW; Diergaarde B; Maxwell JH; Ferris RL; Kim SW; Luvison A; Miller M; Nikiforova MN
BMC Cancer; 2013 Dec; 13():602. PubMed ID: 24341335
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
20. The INPP4B paradox: Like PTEN, but different.
Hamila SA; Ooms LM; Rodgers SJ; Mitchell CA
Adv Biol Regul; 2021 Dec; 82():100817. PubMed ID: 34216856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
